Currently, 55 million people live with dementia worldwide, and this number is estimated to increase more than threefold (~139 million) by 2050. Alzheimer’s disease, one of the most prominent types of dementia, characterizes by the increased deposition of extracellular insoluble plaques composed of amyloid-beta peptide. Recent studies demonstrate that small and soluble amyloid-beta oligomers are sufficient to impair synaptic function and represent the major toxic agents. For this reason, different assembles of amyloid-beta have been considered as important biomarkers for the diagnosis and thera ...